Polski Bank Komórek Macierzystych (PBKM) has a list of several potential companies that it may take over in the next 1-1.5 years. In total, it may spend up to EUR 25 million on their acquisitions. The company will obtain funds for the upcoming acquisitions from the new issue of L shares, the management board has announced. In a broader perspective, it assumes going beyond Europe. If these plans are implemented, the company may spend up to EUR 150mn on acquisitions.
In September, PBKM finalised the acquisition of the Portuguese company Stemlab for PLN 75.1m. It is one of the largest umbilical cord blood banks in Europe, with a 60% share in the Spanish market. Earlier, in May 2018, the company signed an agreement to purchase 100% of shares in Biocell Lugano, a laboratory in Switzerland. The value of that transaction was PLN 6.9 million.
Thanks to the acquisition, the number of umbilical cord blood or tissue samples stored by the Group at the end of the third quarter of 2018 amounted to nearly 227 thousand. Earlier strategic goals assumed reaching 200 thousand only in the middle of 2020. For comparison, in 2014, this number amounted to 94 thousand. These data refer to the segment of individual customers.
In the first three quarters of 2018, PBKM’s revenue amounted to PLN 114.3m. In the corresponding period of the previous year, the figure was PLN 104.7m. Net profit was PLN 29.5m, compared to PLN 17.3m a year earlier.
Outside Poland, the company operates under the FamiCord Group brand. Its share in the European market is about 30%. In total, the 10 largest banks control 60% of the European market, according to PBKM.